Literature DB >> 14656210

Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells.

M E Street1, F Miraki-Moud, I R Sanderson, M O Savage, G Giovannelli, S Bernasconi, C Camacho-Hübner.   

Abstract

Chronic inflammation is characterised by modifications in cytokine concentrations, whereas growth is mainly dependent on the GH-IGF axis. IGF-I bioavailability is modulated by a family of IGF-binding proteins (IGFBPs). The aim of the present study was to evaluate the interactions among interleukin-1beta (IL-1beta), IL-6 and IGFBP secretion by intestinal cells to assess whether cytokines modulate IGFBP secretion, and in turn IGF-I and IGF-II bioavailability. The human colon carcinoma derived cell line Caco-2 was used as an in vitro model for its capacity to differentiate spontaneously. Experiments were carried out on day 4 (undifferentiated state) and day 14 (differentiated state) after plating. Carcinoembryonic antigen (CEA) was used as a marker of differentiation and increased in the conditioned media (CM) from days 4 to 14 (0.2+/-0.01 ng/ml per 10(5) cells vs 3.3+/-0.2 ng/ml per 10(5) cells, P<0.05). IGFBP-2 and IGFBP-4 secretion decreased concomitantly. Cells were stimulated with IL-1beta and IL-6 at 1, 10 and 50 ng/ml, and with IL-1beta and IL-6 in combination at the same dose of 1 and 10 ng/ml. IGF-I at 50 ng/ml was used as a control. Caco-2 cells expressed and secreted mainly IGFBP-2 and IGFBP-4 into the CM. On day 4, IL-1beta (1 ng/ml) and IL-6 (10 and 50 ng/ml) reduced IGFBP-2 by 29+/-8%, and by 32+/-9 and 38+/-8% respectively (P<0.05). IGFBP-4 was also reduced by IL-1beta at 1 and 50 ng/ml (-14+/-4% and -46+/-11% vs serum free medium (SFM) respectively, P<0.05), and IL-6 at 50 ng/ml (-46+/-15%, P<0.05). Both IGFBP-2 and IGFBP-4 were reduced by IL-1beta and IL-6 in combination at 1 and 10 ng/ml (P<0.05). On day 14, IGFBP-2 band intensity was reduced at 10 ng/ml of IL-1beta (-22+/-15% vs SFM, P<0.05) and at 50 ng/ml of both cytokines (-33%+/-8% and -13%+/-13% vs baseline respectively, P<0.05). IGFBP-4 band intensity decreased with 10 and 50 ng/ml of IL-1beta (-35+/-11% and -46+/-15% vs SFM respectively) and IL-6 (-36%+/-10% and -46+/-15% vs SFM respectively). IL-1beta and IL-6 in combination at 1 and 10 ng/ml reduced both IGFBP-2 and IGFBP-4.In conclusion, IGFBP-2 and IGFBP-4 secretion in CM decreased with Caco-2 cell differentiation. IGFBP-2 and IGFBP-4 were significantly decreased by IL-1beta and IL-6 treatment in both the undifferentiated and differentiated state. Furthermore, these cytokines increased cell proliferation whereas total protein content was significantly reduced only at the higher concentrations of IL-6 and IL-1beta. These findings suggest that interleukins modulate the IGF-IGFBP system in Caco-2 cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656210     DOI: 10.1677/joe.0.1790405

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  12 in total

Review 1.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 2.  Diet and lifestyle in survivors of colorectal cancer.

Authors:  Junga Lee; Justin Y Jeon; Jeffrey A Meyerhardt
Journal:  Hematol Oncol Clin North Am       Date:  2015-02       Impact factor: 3.722

Review 3.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

4.  Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers.

Authors:  Simon Keely; Sinéad M Ryan; David M Haddleton; Adam Limer; Giuseppe Mantovani; Evelyn P Murphy; Sean P Colgan; David J Brayden
Journal:  J Control Release       Date:  2008-12-06       Impact factor: 9.776

5.  Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer.

Authors:  Ayman Eldesoky; Ashraf Shouma; Yousef Mosaad; Amira Elhawary
Journal:  Saudi J Gastroenterol       Date:  2011 May-Jun       Impact factor: 2.485

6.  FOXO1 content is reduced in cystic fibrosis and increases with IGF-I treatment.

Authors:  Arianna Smerieri; Luisa Montanini; Luigi Maiuri; Sergio Bernasconi; Maria E Street
Journal:  Int J Mol Sci       Date:  2014-10-08       Impact factor: 5.923

7.  Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model.

Authors:  Raghda T Abdel-Latif; Walaa Wadie; Yousra Abdel-Mottaleb; Dalaal M Abdallah; Nabila N El-Maraghy; Hanan S El-Abhar
Journal:  Saudi Pharm J       Date:  2021-12-31       Impact factor: 4.330

8.  Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro.

Authors:  Vibol Chhor; Tifenn Le Charpentier; Sophie Lebon; Marie-Virgine Oré; Idoia Lara Celador; Julien Josserand; Vincent Degos; Etienne Jacotot; Henrik Hagberg; Karin Sävman; Carina Mallard; Pierre Gressens; Bobbi Fleiss
Journal:  Brain Behav Immun       Date:  2013-02-27       Impact factor: 7.217

9.  Clone-specific expression, transcriptional regulation, and action of interleukin-6 in human colon carcinoma cells.

Authors:  Wolfgang Brozek; Giovanna Bises; Gerhild Fabjani; Heide S Cross; Meinrad Peterlik
Journal:  BMC Cancer       Date:  2008-01-18       Impact factor: 4.430

10.  Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks.

Authors:  Maria E Street; Enzo Grossi; Cecilia Volta; Elena Faleschini; Sergio Bernasconi
Journal:  BMC Pediatr       Date:  2008-06-17       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.